Industries de la santé

Toulouse, le 6 juin 2012 - Vexim (FR0011072602 ALVXM), société Med-Tech spécialisée dans la restauration anatomique mini invasive des fractures vertébrales, annonce la nomination de Marie-Pierre Hontas au poste de Directrice des Affaires Cliniques. Marie-Pierre Hontas dispose de 20 années d'expérience en recherche clinique internationale acquise dans l'industrie pharmaceutique et le...

The U.S. House of Representatives passed its version of the FDA user fee bill ( H.R. 5651) Wednesday 387-5. The vote comes on the heels of the Senate’s 96-1 vote passing their version of the bill ( S. 3187) last week. The different bills would need to be reconciled in a conference committee and receive approval from both chambers before receiving President Obama's signature.

Given...

NEW YORK (GBI Research), 29 May 2012 - Drug resistance and patent expiries are demanding that the antibacterial drug market moves forwards soon, but a current lack of interest from pharmaceutical companies has led to market stagnation, according to a new report by healthcare experts GBI Research.

The new report* shows that while hospital hygiene campaigns to conquer MRSA encourage...

LONDON, UK (GlobalData), 18 May 2012 - The upcoming American Society of Clinical Oncology (ASCO) meeting is one of the most highly anticipated events in the world of cancer pharmaceuticals. This year’s 48th annual meeting will be held in Chicago from June 1-5, and investors and media outlets are already buzzing. The meeting abstracts released by ASCO on Wednesday, May 16 represent a...

Activité R&D accrue avec la préparation du lancement de la Phase IIb

Communication et activité scientifique intense en vue du congrès de l'EAACI

L'AP-HP, partenaire de DBV, présentera lors d'un late breaking abstract : "Six mois d'immunothérapie épicutanée dans l'allergie à l'arachide : innocuité et efficacité"

Nouveau brevet accordé aux Etats-Unis: Viaskin® est désormais le...

LONDON, UK (GlobalData), 14 May 2012 - Recently Compugen, Ltd., an Israel-based biopharmaceutical company with over 17 years of research experience, released animal model data from the company’s proprietary Protein Family Members Discovery Platform. This in-house, in silico bioinformatics system provides a predictive view of protein characteristics leading to gene and protein discovery...

IM Injections of PLX Cells Causing a Dramatic Recovery of Blood Forming Cells

HAIFA, ISRAEL, May 9, 2012 – Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE:PLTR) today announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red cells, white...

Paris, le 3 mai 2012 - NYSE Euronext annonce aujourd'hui l'introduction de Vexim, un acteur de référence de la microchirurgie innovante du dos, sur NYSE Alternext à Paris.






Fondée en 2006 et basée à Toulouse, Vexim est spécialisée dans le traitement mini-invasif des fractures vertébrales par compression, et a entièrement conçu, développé et commercialisé SpineJack®...

Vitrines Sociétés

Voir toutes les vitrines